Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 1, 2011, Pages 59-62

  Ud Din, Nasir ^a   Qureshi, Asim ^b   Mansoor, Samina ^b  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

Author keywords

p63; prostate; prostatic adenocarcinomas; urinary bladder; urothelial carcinomas

Indexed keywords

PROTEIN P63;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MICROSCOPY; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 79952975078     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.77326     Document Type: Article

References (18)

1. Rafique M, Javed AA. Clinico-pathological features of bladder carcinoma: Experience from a tertiary care hospital of Pakistan. Int Urol Nephrol 2006;38:247-50. (Pubitemid 44138148)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Esimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6. (Pubitemid 32911406)
3. Wallace DM. Occupational urothelial cancer. Br J Urol 1988;61:175-82. (Pubitemid 18085411)
4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics 2000. CA Cancer J Clin 2000;50:7-33.
5. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC. Cancer surveillance series: Interpreting trends in prostate cancer- part 1: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24. (Pubitemid 29293040)
6. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998;110:385-90. (Pubitemid 28406998)
7. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007;31:673-80. (Pubitemid 46684205)
8. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1759-75.
9. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: Review of current literature. Histopathology 2005;47:1-16. (Pubitemid 40978808)
10. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. Am J Clin Pathol 2002;118:202-7. (Pubitemid 44698443)
11. Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: Need for standardisation and stringent quality assurance in PSA and PSAP Immunostaining. J Clin Pathol 2004;57:687-90. (Pubitemid 38901480)
12. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-404. (Pubitemid 33022055)
13. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12+ p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003;27:365-71. (Pubitemid 36245802)
14. Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol 2000;113:383-8. (Pubitemid 30217386)
15. Kaufmann O, Volmerig J, Dietel M. Uroplakin 3rd is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol 2000;113:683-7. (Pubitemid 33044309)
16. Kunju LP, Mehra R, Snyder M, Shah R. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/ or p63: An optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006;125:675-81.
17. Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R. p63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem 2003;51:1097-9. (Pubitemid 36919987)
18. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.